Oral Cancer Chemoprevention--The End of EPOC, the Beginning of an Epoch of Molecular Selection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions.JCI insight · 2021
   Trial
2. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective.Journal of personalized medicine · 2022
   Review
3. AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health.Cancer prevention research (Philadelphia, Pa.) · 2018
   Article
4. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.Journal of hepatology · 2018
   Review
5. Future cancer research priorities in the USA: a Lancet Oncology Commission.The Lancet. Oncology · 2017
   Review
6. When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials.Cancer prevention research (Philadelphia, Pa.) · 2017
   Article
7. Precancer Atlas to Drive Precision Prevention Trials.Cancer research · 2017
   Article
8. The Conundrum of Genetic "Drivers" in Benign Conditions.Journal of the National Cancer Institute · 2016
   Review
9. Transforming Cancer Prevention through Precision Medicine and Immune-oncology.Cancer prevention research (Philadelphia, Pa.) · 2016
   Article
10. Immunological and classical subtypes of oral premalignant lesions.Oncoimmunology
    Article

Corrections and comments

• Comment on
  Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as